Article Sidebar

Submitted
September 18, 2019
Accepted
December 29, 2019
Published
December 30, 2019
Download
PDF
Statistic
Read Counter : 636 Download : 574

Main Article Content

Abstract

Positioning in the top list of mortality and morbidity, cardiovascular disease (CVD) is required new approaches to mitigate the risk and prevalence. Recombinant DNA (rDNA) technology and genome sequencing explore the new horizon to treat CVD through modified therapy. Gene transfer mechanism eventually angiogenic gene therapy provides efficacy in early-stage heart failure. Targeted gene delivery system depicts the novel therapeutic pattern for both genetic disorder and pathophysiological deficit and opens the pathway of early diagnose and treatment. Despite  some limitations of a specific vector (viral vector) mediated gene transfer, these new approaches make  hope on CVD treatment rather than the surgery and other ways.  Furthermore, some vectors are less hazardous than viral vectors to suggest successful non-viral gene modulations to Cardiovascular tissues and perform in the clinical trial. However, plasmid-mediated gene transfer method along with genome editing technology might be the best possible approach for future CVD prognostics and diagnostics.

Keywords

CVD Gene transfer Gene therapy Plasmid

Article Details

Author Biography

Syaefudin Ali Akhmad, (Scopus ID: 55735744200), Department of Biochemistry, Faculty of Medicine, Universitas Islam Indonesia, Yogyakarta

Scopus: http://www.scopus.com/inward/authorDetails.url?authorID=55735744200
How to Cite
Raqib, S. M., & Akhmad, S. A. (2019). Evaluation of vector mediated gene therapy as a novel approach to mitigate cardiovascular diseases; A short review. JKKI : Jurnal Kedokteran Dan Kesehatan Indonesia, 10(3), 281–286. https://doi.org/10.20885/JKKI.Vol10.Iss3.art11
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Hajjar RJ. Potential of gene therapy as a treatment for heart failure. Journal of Clinical Investigation. 2013; 123(1):53–61.
  2. Yeates K, Lohfeld L, Sleeth J, Morales F, Rajkotia Y, and Ogedegbe O. A global perspective on cardiovascular disease in vulnerable populations. Canadian Journal of Cardiology. 2015; 31(9): 1081–1093
  3. Patoulias D, Stavropoulos K, Imprialos K, Athyros V, Doumas M, and Karagiannis A. Pharmacological management of cardiac disease in patients with type 2 diabetes: Insights into clinical practice. Current Vascular Pharmacology. 2019;17
  4. Pasipoularides A. Implementing genome-driven personalized cardiology in clinical practice. Journal of Molecular and Cellular Cardiology. 2018; 115:142–157.
  5. Generation N, Threats B, and Affairs G. Globalization, biosecurity, and the future of the life sciences. Washington, DC: The National Academies Press National Research Council 2006.
  6. Valsalakumari J, Baby J, Bijin E, Constantine I, Manjila S, and Pramod K. Novel gene delivery systems. International Journal of Pharmaceutical Investigation. 2013; 3(1); 1.
  7. Katz MG, Fargnoli AS, Gubara SM, Fish K, Weber T, Bridges CR et al. Targeted gene delivery through the respiratory system: rationale for intratracheal gene transfer. Journal of Cardiovascular Development and Disease. 2019; 6(1); 8.
  8. Slade N.Viral vectors in gene therapy. in Periodicum Biologorum.2001;103(2); 139–143.
  9. Choi KH. Viral Polymerases.Advances in Experimental Medicine and Biology. 2016.
  10. Mátrai J, Chuah MK, and Vandendriessche T. Recent advances in lentiviral vector development and applications. Molecular Therapy. 2010:18(3): . 477–490.
  11. Hoban MD and Bauer DE. Review series genome editing in hematology a genome editing primer for the hematologist.2016.
  12. Lee CS, Bishop ES, Zhang R, Yu X, Farina EM, Yan S, et al. .Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes and Diseases. 2017:.4(2): 43–63
  13. Lopez-Gordo E, Podgorski II, Downes N, and Alemany R. Circumventing antivector immunity: Potential use of nonhuman adenoviral vectors.Human Gene Therapy.. 2014; 25(4):285–300.
  14. Berns KI and Muzyczka N.AAV: An overview of unanswered questions. Human Gene Therapy.2017;28(4): 308–313.
  15. Kawase Y, Ladage D, and Hajjar RJ. Rescuing the failing heart by targeted gene transfer. Journal of the American College of Cardiology. 2011; 57(10); 1169–1180.
  16. Ibraheem D, Elaissari A, and Fessi H.Gene therapy and DNA delivery systems. International Journal of Pharmaceutics. 2014; 459(1–2): 70–83.
  17. Templeton NS. Cationic liposome-mediated gene delivery in vivo. Bioscience Reports. 2002; 22(2).
  18. Chakalova L and Fraser P. Organization of transcription. Cold Spring Harbor perspectives in biology. 2010; 2(9).
  19. Hastings CL, Roche ET, Ruiz-Hernandez E, Schenke-Layland K, Walsh CJ, and Duffy GP. Drug and cell delivery for cardiac regeneration. Advanced Drug Delivery Reviews. 2015; 84: 85–106.
  20. Lam MK, Tandjung K, Sen H, Basalus MWZ, van Houwelingen G, Stoel MG et al..Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: Insights from the prospective, randomised Twente trial. EuroIntervention. 2015; 11(2): 180–187.
  21. Katz MG, Fargnoli AS, Williams RD, and Bridges CR. Gene therapy delivery systems for enhancing viral and nonviral vectors for cardiac diseases: Current concepts and future applications. Human Gene Therapy. 2013;24(11):914–927.
  22. Ginn SL, Amaya AK, Alexander IE, Edelstein M, and Abedi MR. Gene therapy clinical trials worldwide to 2017: An update. Journal of Gene Medicine. 2018; 20(5).
  23. Maeder ML and Gersbach CA. Genome-editing technologies for gene and cell therapy. Molecular Therapy. 2016; 24(3): 430–446.
  24. Bradshaw AC and Baker AH. Gene therapy for cardiovascular disease: Perspectives and potential. Vascular Pharmacology. 2013; 58(3): 174–181.
  25. Wolfram JA and Donahue JK. Gene therapy to treat cardiovascular disease.Journal of the American Heart Association. 2013;2(4).